FIRST TIME VISITOR? CLICK HERE!

Welcome to AIDS-Drugs-Online.com.

Our website ensures an easy ordering process for affordable HIV/AIDS and PrEP medications, as well as protection of our customers' information. Having an account on our website allows you to place your orders easily, upload your prescriptions safely, view your order history, and even earn discounts.

If you have not ordered from us before:
You can create an account for free by clicking here.

Please take a moment to learn how to order. If you have any trouble, please call us at 1-888-243-7675.

Australia: +61 (2) 90537441 Switzerland: +41 (44) 7982088

We invite you to explore our website and save money on your HIV/AIDS and PrEP medications!


Atripla 600/200/300 Mg
30 tablet(s)

Atripla 600/200/300 Mg

$1,599.99 USD
+ shipping and handling
0 Review(s)

Prescription required

Active Ingredient(s): efavirenz/ emtricitabine/ tenofovir
Manufacturer: Gilead Sciences
Brand: Yes
Country of origin: Canada
Known Names: Viraday, Vonavir
30 tablet(s)
Active Ingredient(s): efavirenz/ emtricitabine/ tenofovir
Manufacturer: Gilead Sciences
Brand: Yes
Country of origin: Canada
Knows Names: Viraday, Vonavir

What is Atripla (Efavirenz / Emtricitabine / Tenofovir)?

Atripla is an oral antiretroviral medication for the treatment of HIV-1 in adults and children weighing above 40 kg. This three-drug combination contains the Efavirenz (EFV), a non-nucleoside reverse transcriptase inhibitor, and Emtricitabine (FTC) and Tenofovir Disoproxil Fumarate (TDF), which are two HIV-1 nucleoside analog reverse transcriptase inhibitors. Atripla HIV medication represents a significant development in the treatment of HIV-1, as it was developed as a part of a joint corporate venture and is the first ever triple-therapy offering. It received approval from the FDA in 2006 and from Health Canada in 2007. The drug is a convenient and effective antiretroviral combination product that is a natural fit for current HIV management guidelines. It provides a simplified approach to effective HIV management for patients and physicians.

Dosing & Administration

Current Canadian adult guidelines recommend the treatment of all HIV-positive patients with antiretroviral therapy. This includes treatment on an immediate basis during chronic HIV infection, regardless of CD4 counts, and during the acute phase of the primary infection with HIV. Antiretroviral therapy is especially urgent in cases of pregnancy, symptomatic infection, co-infection with chronic hepatitis B or C, higher viral loads, lower CD4 count, and other specific situations.

Medication compliance is especially crucial in HIV therapies because of rapid viral resistance development. Fixed-dose single-tablet combination antiretrovirals such as Atripla may improve a patient’s adherence to the drug regimen, which lends a significant therapeutic advantage to this combination medication.

Atripla is indicated for first-line use in drug-naïve patients, usually at a dose of one tablet at bedtime on an empty stomach. It may be used alone or in combination with other antiretroviral agents for the treatment of HIV-1.

Contraindications

Atripla tablet should not be used in patients with moderate to severe renal failure, including patients with an estimated creatinine clearance below 50 mL/min. Additionally, this medication should be used with caution in patients with mild hepatic impairment, and it should not be used at all in patients with moderate to severe hepatic impairment.

Atripla Side Effects

The side effects include the following:

  • immune reconstitution inflammatory syndrome, or IRIS;
  • osteopenia;
  • lactic acidosis.

The list above is not exhaustive. For more information on this medication’s side effects, refer to the product’s package insert.

Medication Precautions

  1. All patients should be tested for the presence of chronic Hepatitis B Virus (HBV) infection prior to starting antiretroviral therapy, including Atripla, due to reports of severe acute exacerbations of HBV after the discontinuation of FTC and TDF, both of which are contained in this medicine.
  2. Current HIV treatment guidelines recommend testing HIV-positive patients for the Hepatitis C virus (HCV) and regular ongoing testing for those deemed to be to high risk. If HIV/HCV co-infection is identified, consideration should be given to treating both infections concurrently.

Drug Interactions

Atripla’s key drug interactions are with Cytochrome P450 metabolized medications, but there is a long list of drug-drug interactions that should be reviewed in the package insert prior to prescribing.

Pregnancy & Lactation

The drug may cause neural tube defects, so it should not be used during pregnancy. Any inadvertent use during pregnancy should be reported to the Antiretroviral Pregnancy Registry. Pregnancy testing in female patients of child-bearing age should be done prior to the initiation of treatment with Atripla, and effective birth control should be used during therapy with this drug and for 12 weeks after therapy with the medication.

Overdosage

In the case of an overdose with this medication, monitor the patient to see if there is any evidence for toxicity. Apply standard supportive treatment. For more information about what to do in case of an overdose with Atripla, refer to the medication’s package insert.

There are no reviews yet
Be the first to review “Atripla 600/200/300 Mg”
Star

Reviews are only written by verified customers who have purchased this product.

Related Products

Tenvir EM 200/300 Mg

Tenvir EM 200/300 Mg

from $65.00 USD
Abamune-L 600/300 Mg

Abamune-L 600/300 Mg

from $98.00 USD
Viraday 600/200/300 Mg

Viraday 600/200/300 Mg

from $98.00 USD
Efavir 600 Mg

Efavir 600 Mg

from $65.00 USD

Reset your password

Please enter your email below, and we will send you a new password.

Still having trouble signing in?

If you're unable to reset your password, please call Customer Service at 1-888-243-7675.